Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Ansell

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
British Journal of Cancer|November 18, 2010
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphomaA Younes, J M Vose, A D Zelenetz, et al.
Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Bone Marrow Transplantation|April 25, 2006
Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphomaF K Buadi, I N Micallef, S M Ansell, et al.
Blood|July 27, 2001
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphomaL F Porrata, M A Gertz, D J Inwards, et al.
Leukemia|May 21, 2010
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphomaL F Porrata, K Rsitow, D J Inwards, et al.
Leukemia|December 8, 2010
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaT E Witzig, C B Reeder, B R LaPlant, et al.
Leukemia|May 25, 2011
The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphomaR A Wilcox, K Ristow, T M Habermann, et al.
Blood Cancer Journal|August 1, 2015
IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphomaB Xiu, Y Lin, D M Grote, et al.
Leukemia|October 22, 2011
Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphomaS M Ansell, H Tang, P J Kurtin, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|November 18, 2010
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphomaA Younes, J M Vose, A D Zelenetz, et al.
Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Bone Marrow Transplantation|April 25, 2006
Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphomaF K Buadi, I N Micallef, S M Ansell, et al.
Blood|July 27, 2001
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphomaL F Porrata, M A Gertz, D J Inwards, et al.
Leukemia|May 21, 2010
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphomaL F Porrata, K Rsitow, D J Inwards, et al.
Leukemia|December 8, 2010
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaT E Witzig, C B Reeder, B R LaPlant, et al.
Leukemia|May 25, 2011
The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphomaR A Wilcox, K Ristow, T M Habermann, et al.
Blood Cancer Journal|August 1, 2015
IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphomaB Xiu, Y Lin, D M Grote, et al.
Leukemia|October 22, 2011
Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphomaS M Ansell, H Tang, P J Kurtin, et al.
Pageof 8